Compare Grab Holdings Ltd. (GRAB) vs Moderna, Inc. (MRNA) Price & Performance

GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $30M CEO share purchase and acquisition of Atome Financial, signaling management confidence and financial services expansion.

GRAB presents a turnaround story with improving profitability and analyst support (91.7% buy ratings), though technical indicators remain bearish. Key risks include aggressive capital deployment and regional regulatory challenges. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in Southeast Asia.

Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.

While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.